EyePoint Q3 2025 Financial Results & Corporate Highlights
EyePoint Pharmaceuticals has fully enrolled its two Phase 3 trials in wet age-related macular degeneration (LUGANO and LUCIA), initiated...
Moonlake Reports Q3 Financials, New Sonelokimab Trial Data
MoonLake Immunotherapeutics reported third-quarter 2025 results and a cascade of clinical updates that set up sonelokimab for a pivotal...
Inotiv Reports Q4 and Full-Year 2025 Financial Results
Inotiv reported fourth-quarter fiscal 2025 revenue of $138.1 million, up 5.9% year over year, and full-year revenue of $513.0...
BioCryst’s Successful Astria Acquisition Gets Early Approval
BioCryst Pharmaceuticals received early termination of the Hart-Scott-Rodino waiting period for its proposed acquisition of Astria Therapeutics, clearing a...
Tokyo Pharma Founder, Chairman Acquires Company Shares
OKYO Pharma’s executive chairman, through an affiliated entity, has increased his stake in the company by purchasing 27,051 additional...
Catalyst Pharmaceuticals Reports Q3 2025 Financial Results
Catalyst Pharmaceuticals posted third-quarter 2025 revenue of $148.4 million, up 17% year over year, and raised full-year guidance to...
Neurothera Eyes Promising Stake in Quantum Bio-Data Company
NeuroThera Labs, the clinical-stage subsidiary majority-owned by SciSparc, has signed a non-binding term sheet to acquire a 55% stake...
First Komzifti Sale Triggers $135M Kura Oncology Payout
Kura Oncology has recorded the first U.S. commercial sale of Komzifti (ziftomenib), its once-daily oral menin inhibitor approved on...
Newgen Reports Powerful Growth, NAV Strengthened to $66.75
NewgenIVF Group reported a sharp swing to profitability for the first nine months of 2025, posting $17.5 million in...
PEDMARK® Study in Japan Shows Positive Hearing Loss Results
Fennec Pharmaceuticals reported positive topline results from the investigator-initiated STS-J01 Phase 2/3 study in Japan evaluating Pedmark (sodium thiosulfate)...